KTTA — Pasithea Therapeutics Cashflow Statement
0.000.00%
- $6.10m
- -$5.91m
- 18
- 53
- 31
- 26
Annual cashflow statement for Pasithea Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -0.041 | -2.17 | -11.7 | -15.5 |
Depreciation | ||||
Amortisation | ||||
Non-Cash Items | — | -1.11 | -2.81 | -0.14 |
Discontinued Operations | ||||
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.002 | 0.111 | 0.845 | 1.57 |
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accrued Expenses | ||||
Change in Payable / Accrued Expenses | ||||
Cash from Operating Activities | -0.039 | -3.17 | -13.7 | -13.4 |
Capital Expenditures | — | -0.021 | -0.107 | -0.034 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | — | — | -2.82 | 0.433 |
Acquisition of Business | ||||
Sale of Business | ||||
Sale of Fixed Assets | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | — | -0.021 | -2.93 | 0.399 |
Financing Cash Flow Items | — | 20.6 | 0 | 0 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 0.282 | 55.9 | -3.21 | -3.73 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 0.244 | 52.7 | -19.8 | -16.8 |